secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001558370-24-016445
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix repays all convertible notes, becomes debt-free; EMA validates Fabry drug dosing variation
--------------------------------------------------------------------------------

- Repaid in full all outstanding convertible notes, making company debt-free.
- EMA validated Chiesi's variation submission for pegunigalsidase alfa every-four-week dosing in EU.
- Completed Phase I trial of PRX-115 for uncontrolled gout; Phase II planned H2 2025.
- Revenue streams from Elfabrio, Elelyso, and Uplyso growing; full operations maintained despite Israel conflict.
- Fine-tuned R&D strategy on renal rare diseases and plant-based drug delivery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024016445/0001558370-24-016445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024016445/plx-20241223x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer